Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACLOVATE vs AEROSEB-DEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
The combination product contains a corticosteroid (dexamethasone) which suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and a topical antibiotic (usually neomycin or polymyxin B) which inhibits bacterial protein synthesis or disrupts bacterial cell membranes.
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., atopic dermatitis, contact dermatitis, eczema, psoriasis) - FDA approved,Off-label: Treatment of mild to moderate plaque psoriasis, seborrheic dermatitis, and lichen planus
Ophthalmic corticosteroid-responsive inflammatory conditions with concurrent bacterial infection or risk of infection,Blepharitis,Conjunctivitis,Keratitis,Iritis,Cyclitis
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
2 puffs (100 mcg each) intranasally twice daily
Terminal elimination half-life: approximately 6-8 hours after topical application; systemic absorption is minimal under normal use.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Aclovate is metabolized in the skin and liver via ester hydrolysis to inactive metabolites. Systemic metabolism primarily involves cytochrome P450 enzymes (CYP3A4) for any absorbed fraction, but extensive first-pass metabolism limits systemic exposure.
Dexamethasone is metabolized primarily in the liver via CYP3A4; topical antibiotics (neomycin, polymyxin B) are minimally absorbed and not significantly metabolized.
Renal (primarily as metabolites, <5% unchanged), biliary/fecal (minor).
Renal elimination of unchanged drug accounts for 30-40% of the dose; fecal/biliary elimination is 50-60% as metabolites. Less than 10% is excreted unchanged in feces.
Approximately 90%, primarily to albumin and corticosteroid-binding globulin (CBG).
Approximately 85% bound to serum albumin and alpha-1-acid glycoprotein.
Not well-characterized in topical use; after systemic absorption, Vd is approximately 1-2 L/kg, indicating distribution into tissues.
Vd is 3-4 L/kg, indicating extensive tissue distribution with accumulation in liver and kidneys.
Topical: approximately 1-3% systemic absorption on intact skin; increased up to 15% on occluded or damaged skin.
Oral: 40-50% due to first-pass metabolism; Topical: 5-10% systemically; IV: 100%.
No dose adjustment required. Topical use with minimal systemic absorption.
No adjustment required for any GFR level
No dose adjustment required. Topical use with minimal systemic absorption.
Child-Pugh Class A: no adjustment; Child-Pugh Class B/C: no data available; use with caution
Use smallest amount effective for shortest duration. Avoid prolonged use, occlusive dressings, or application to large surface areas. Safety in children <1 year not established.
Children 6-11 years: 1 puff (50 mcg) per nostril twice daily; Children ≥12 years: same as adult
Use with caution due to increased risk of skin atrophy and systemic absorption. Limit frequency and duration; avoid occlusive dressings.
No specific dose adjustment; monitor for adrenal suppression and osteoporosis risk with prolonged use
No FDA black box warning.
Prolonged use may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Prolonged use may suppress the host response and thus increase the hazard of secondary ocular infections. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids.
Topical corticosteroids can cause hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with prolonged use, large surface area, occlusion, or in pediatric patients.,Reversible HPA axis suppression may occur after discontinuation.,Systemic effects including Cushing's syndrome, hyperglycemia, and glucosuria have been reported.,Local adverse reactions: burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria.,Use caution in patients with impaired skin integrity or areas of skin atrophy.,Pediatric patients may be more susceptible to systemic toxicity due to higher skin surface-to-body-weight ratio.
Prolonged use may lead to ocular hypertension/glaucoma,Posterior subcapsular cataract formation,Delayed wound healing,Secondary ocular infections (including fungal infections),Corneal/scleral thinning and perforation,Systemic absorption with prolonged use (especially in children),Avoid use in patients with known hypersensitivity to any component
Hypersensitivity to alclometasone dipropionate or any component of the formulation.,Untreated bacterial, fungal, or viral skin infections (e.g., herpes simplex, varicella, tuberculosis of the skin).
Epithelial herpes simplex keratitis (dendritic keratitis),Vaccinia, varicella, and other viral infections of the cornea and conjunctiva,Mycobacterial infections of the eye,Fungal diseases of ocular structures,Hypersensitivity to any component of the formulation
No known food interactions with topical Aclovate.
No specific food interactions. Avoid grapefruit juice as it may increase systemic exposure to ciclesonide via CYP3A4 inhibition.
Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be ruled out. Avoid extensive use or prolonged treatment, especially in first trimester. Second and third trimester: Use only if clearly needed, minimal area and duration.
Pregnancy Category C. First trimester: potential for teratogenicity based on animal studies; avoid unless benefit outweighs risk. Second/third trimester: drug may cause fetal harm due to pharmacological effects; use only if clearly needed.
Safety unknown; likely minimal systemic absorption due to low potency. M/P ratio not established. Avoid application to breasts or large areas; use caution.
Excreted in human milk in unknown amounts; M/P ratio not established. Caution advised due to potential for serious adverse reactions in nursing infants; discontinue drug or nursing depending on importance to mother.
No standard dose adjustment required; however, limit potency, frequency, and duration to lowest effective due to altered skin permeability. No pharmacokinetic changes necessitate dose change.
No established dose adjustments in pregnancy; pharmacokinetics may be altered due to increased plasma volume and metabolism. Use lowest effective dose; individualize therapy based on clinical response.
Topical corticosteroids like Aclovate are classified as low-potency (Group VI). They are suitable for thin skin areas (e.g., face, flexures) and for children. Avoid prolonged use without interruption to minimize systemic absorption, especially in pediatric patients due to higher skin surface area-to-body weight ratio.
AEROSEB-DEX is a fixed-dose combination of an inhaled corticosteroid (ciclesonide) and a long-acting beta-agonist (formoterol). Use as maintenance therapy for asthma, not for acute bronchospasm. Rinse mouth after inhalation to prevent oral candidiasis. Monitor for adrenal suppression with prolonged use. Dose formoterol component at low to moderate doses to minimize risk of asthma-related death.
Apply a thin layer to affected skin only, not to normal surrounding skin.,Do not cover with bandages or dressings unless directed by your doctor.,Use for the prescribed duration; do not use longer than 2 weeks at a time.,Avoid contact with eyes, mouth, and open wounds.,Report any signs of skin thinning, redness, or irritation to your healthcare provider.
Use regularly as prescribed, not for sudden breathing problems.,Rinse mouth with water after each use to prevent thrush.,Do not stop suddenly; taper under doctor guidance.,Seek emergency if rescue inhaler not effective.,Report worsening asthma, chest pain, or signs of steroid excess.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACLOVATE vs AEROSEB-DEX, answered by our medical review team.
ACLOVATE is a Topical Corticosteroid that works by Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.. AEROSEB-DEX is a Topical Corticosteroid that works by The combination product contains a corticosteroid (dexamethasone) which suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and a topical antibiotic (usually neomycin or polymyxin B) which inhibits bacterial protein synthesis or disrupts bacterial cell membranes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACLOVATE and AEROSEB-DEX depend on the specific clinical indication. These are both Topical Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACLOVATE is: Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.. The standard adult dose of AEROSEB-DEX is: 2 puffs (100 mcg each) intranasally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACLOVATE and AEROSEB-DEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACLOVATE is classified as Category C. Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be . AEROSEB-DEX is classified as Category C. Pregnancy Category C. First trimester: potential for teratogenicity based on animal studies; avoid unless benefit outweighs risk. Second/third trimester: drug may cause fetal harm . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.